Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | QPCT | Q16769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12410299 | 0.85 | PIK3CA (0.57) | CHEK1NOTUM | |
| SCHEMBL2361098 | 0.78 | HTT (0.91) | EPHX1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL12974657 | 0.77 | EPHX1 (0.63) | EPHX1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL14424481 | 0.77 | EPHX1 (0.97) | EPHX1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL17954337 | 0.76 | EPHX1 (0.48) | EPHX1 | |
| SCHEMBL12196033 | 0.76 | EPHX1 (1.00) | EPHX1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL30567117 | 0.76 | DEGS1 (0.67) | EPHX1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL2574821 | 0.76 | CHEK1 (0.52) | HTTALDH1A1CHEK1NOTUM | |
| SCHEMBL22581730 | 0.76 | DEGS1 (0.67) | EPHX1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL26758609 | 0.76 | RAB9A (0.65) | EPHX1HTTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889676-B2 | 3-ureidoisoquinolin-8-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| EP-2552893-B1 | ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-10-29 | — | — | EP | disclosed |
| US-20140038961-A1 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-02-06 | — | — | US | disclosed |
| EP-2691373-A1 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2014-02-05 | — | — | EP | disclosed |
| US-20130096119-A1 | Isoquinolin-3-Ylurea Derivatives | BUR DANIEL (CH) | 2013-04-18 | — | — | US | disclosed |
| EP-2552893-A1 | ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2013-02-06 | — | — | EP | disclosed |
| WO-2012131588-A1 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-10-04 | — | — | WO | disclosed |
| WO-2011121555-A1 | ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096119-A1 | Isoquinolin-3-Ylurea Derivatives | CLIC1, IRF3, KCNH3 | EPHX1 1560/4885HTT 2696/4885SMN1; SMN2 4732/4885 |
| US-20140038961-A1 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES | CBR3, CBR1, REL | EPHX1 1209/4885HTT 2655/4885SMN1; SMN2 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.